Analysts Offer Insights on Healthcare Companies: Kite Pharma (NASDAQ: KITE), Alnylam Pharma (NASDAQ: ALNY) and Corium (NASDAQ: CORI)By Ryan Adsit
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kite Pharma (NASDAQ: KITE), Alnylam Pharma (NASDAQ: ALNY) and Corium (NASDAQ: CORI) with bullish sentiments.
Kite Pharma (NASDAQ: KITE)
“Recently, a debate has arisen over pot’l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics around the word “relapsed”. We believe little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed pts are healthier than refractory pts.”
According to TipRanks.com, Amin is a 4-star analyst with an average return of 4.2% and a 51.5% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.
Currently, the analyst consensus on Kite Pharma is Strong Buy and the average price target is $72, representing a 39.3% upside.
In a report issued on November 10, RBC Capital also maintained a Buy rating on the stock with a $85 price target.
Alnylam Pharma (NASDAQ: ALNY)
“We hosted dinner with ALNY in Boston. Mgmt addressed safety concerns on several programs and believed that ALN-AAT termination was due to RNAi sequence while the revusiran discontinuation was likely program-specific. Additional analysis of revusiran Ph3 data continues with high-level update expected at R&D day (more meaningful data in early-17).”
According to TipRanks.com, Wang is ranked 0 out of 5 stars with an average return of -17.1% and a 37.2% success rate. Wang covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Cascadian Therapeutics, and Atara Biotherapeutics.
Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $65, representing a 42.4% upside.
In a report issued on November 15, Piper Jaffray also reiterated a Buy rating on the stock with a $106 price target.
Corium (NASDAQ: CORI)
“CORI’S F4Q loss was slightly narrower than our est (-$9.3M vs $10.3M JEF) primarily reflecting lower G&A spend (-$700k vs JEF) while revs of $7.9M were in line with our forecast. With two potentially high-value Alzheimer’s programs quickly advancing toward late-stage development and a key Ph3 readout for partner AGRX’s Twirla contraceptive patch in early January, CORI shares continue to look significantly undervalued in our view. F4Q Revs Again Driven by P&G Whitestrips; Weakness in Generic Partnered Products Likely to Persist: Mgt indicated that its TD clonidine revs have returned to normal levels following the divestiture of the ANDA from TEVA to Mayne at the end of F3Q while conditions in the generic TD fentanyl market continue to deteriorate with partner ENDP reducing forecasted demand for this product in F1H17. Within the context of a weak pricing environment, mgt expects revs from both clonidine and fentanyl to further decline in FY17.”
According to TipRanks.com, Steinberg is ranked 0 out of 5 stars with an average return of -3.2% and a 40.1% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Corium has an analyst consensus of Strong Buy.